67 Investor presentation First three months of 2021 Biopharm sales growth of 1% dri execution with key brands being DKK billion 25 NovoSeven ® and Norditropin ® account for ~80% of Biopharm sales -16% -1% 4% 1% 1% 20 15 10 5 0 2017 2018 NovoSeven ® Norditropin ® 2019 2020 Q1 2021 Other haemophilia products 1 Other biopharm Growth at CER Note: Company reported sales; CER: Constant exchange rates; 1 Other haemophilia products primarily consists of Vagifem® and Act
Download PDF file